Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination
Authors:
Preprint
Abstract
Two group 2B β-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. The mechanisms of cross protection driven by the sarbecovirus spike, a dominant immunogen, are less clear yet critically important for pan-sarbecovirus vaccine development. We evaluated the mechanisms of cross-sarbecovirus protective immunity using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination did not prevent virus replication, it protected against lethal heterologous disease outcomes in both SARS-CoV-2 and clade 2 bat sarbecovirus HKU3-SRBD challenge models. The spike vaccines tested primarily elicited a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. We found non-neutralizing antibody functions that mediated cross protection in wild-type mice were mechanistically linked to FcgR4 and spike S2-binding antibodies. Protection was lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.Keywords
All Related Versions
- Published version: Cell Reports, 42 (4), 112326.
This publication has 102 references indexed in Scilit:
- Phase I Safety and Immunogenicity Evaluations of an Alphavirus Replicon HIV-1 Subtype CgagVaccine in Healthy HIV-1-Uninfected AdultsClinical and Vaccine Immunology, 2012
- A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon ChallengeJournal of Virology, 2011
- Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutininProceedings of the National Academy of Sciences, 2011
- The aging of the immune systemTransplant International, 2009
- Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in miceProceedings of the National Academy of Sciences, 2008
- The mouse ascending: perspectives for human-disease modelsNature Cell Biology, 2007
- Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike VariantsPLOS Medicine, 2006
- Bats Are Natural Reservoirs of SARS-Like CoronavirusesScience, 2005
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Alphavirus Replicon Particles as Candidate HIV VaccinesIUBMB Life, 2002